Development of High Throughput Molecular Profiles for the Detection and Staging of Cancer

Award Information
Agency:
Department of Defense
Amount:
$729,500.00
Program:
SBIR
Contract:
DAMD17-03-C-0039
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
Army
Award Year:
2003
Phase:
Phase II
Agency Tracking Number:
A022-0079
Solicitation Topic Code:
N/A
Small Business Information
EPITOMICS, INC.
1015 Grandview Drive, South San Francisco, CA, 94080
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
118926596
Principal Investigator
 Dongxiao Zhang
 Vice President of Genomic
 (650) 583-6688
 dongxiao.zhang@epitomics.com
Business Contact
 Guo-Liang Yu
Title: President and CEO
Phone: (650) 583-6688
Email: guoliang.yu@epitomics.com
Research Institution
N/A
Abstract
The discovery and identification of novel tumor associated antigens (TAAs) is critical for the advancement of accurate cancer diagnosis and staging. This Small Business Innovation Research Phase II project aims to continue development and application of anovel technology, Dual Immunostaining mediated Subtractive Cloning (DISC). The technology allows molecular cloning of genes that encode tumor cell surface proteins that are structurally or quantitatively different from those in normal cells. In Phase I,the feasibility of DISC was demonstrated. We have shown that rabbit polyclonal antibodies can be used as a complex probe to discover tumor associated cell surface antigens. Using the tumor cell line HeLa S3 and primary normal human fibroblast cells,polyclonal antibodies against these cell types were purified and effectively labeled using fluorescent dyes. A highly efficient method was established to identify cell surface antigens or unique epitopes, only expressed in tumor cells.In Phase II, DISC will be further developed and used to clone TAAs for human cancers of the breast, the prostate, and the lung. Tumor cell lines, tumor tissues, corresponding normal primary cells and normal tissues will be used to clone TAA genes. In thesame process, rabbit cell lines expressing these TAAs will be obtained. Rabbit monoclonal antibodies against these TAAs will be generated from these TAA expressing cell lines. Tumor specificity of the newly discovered TAAs and commercial potential of therabbit monoclonal antibodies will be evaluated by tumor tissue arrays.In this SBIR Phase II, Epitomics will discover and develop new TAAs and rabbit monoclonal antibodies that will enable 1) the rapid identification and characterization of novel tumor antigen targets and 2) commercial development of diagnostic kits.Epitomcis will supply the TAA genes and rabbit monoclonal antibodies to cancer researchers for clinical studies, commercialize them as research reagents and further develop some of the rabbit monoclonal antibodies into products for cancer staging anddiagnosis.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government